Premium

Trump’s tariff threat on generic drugs: Why this matters for Indian pharma companies

US President Donald Trump’s threat comes after several such ultimatums, largely designed to attract investment in the US. Actual tariffs on drugs have been exempted in most tariff instruments his administration has used so far.

TrumpUS President Donald Trump in the Oval Office at the White House, Washington DC, on July 21, 2026. Photo: AP/Mark Schiefelbein
Written by: Ravi Dutta Mishra
4 min readNew DelhiJul 22, 2026 06:24 PM IST First published on: Jul 22, 2026 at 06:24 PM IST

US President Donald Trump on Tuesday (July 21) said that tariffs on generic drugs in the US will be raised 100% after two years and to 200% thereafter to “reshore” generic pharma production in the US, adding that companies deciding against building plants in the US will be “penalised”.

Trump’s threat comes after several such ultimatums, largely designed to attract investment in the US. Actual tariffs on drugs have been exempted in most tariff instruments his administration has used, starting with those under the International Emergency Economic Powers Act, Section 122 of the 1974 Trade Act, and Section 232 of the Trade Expansion Act of 1962.

Advertisement

Here’s why this assumes significance for India and how Indian pharma giants are already changing tack in terms of investments in the US.

Ravi Dutta Mishra is a Pr... Read More

Latest Comment
Post Comment
Read Comments